Simplifying the Complexity of Available Biologic Treatments for Psoriasis: Tips on the Use of Anti-IL-23 Drugs in Psoriasis

Faculty
Learning Objectives
Intended Audience
Accreditation Statement
Credit Designation Statement
Disclosure
Disclaimer

Mark Lebwohl, MD

Faculty

Dean for Clinical Therapeutics
Waldman Professor and Chairman
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Upon completion of this activity, the participant should be better able to:

Understand the mechanism of anti-IL-23 antibodies
Identify features of anti-IL-23 antibodies that result in different clinical outcomes
Recognize particular patient scenarios where therapy with an anti-IL-23 antibody could be useful

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and the Foundation for Research and Education in Dermatology. The Institute is accredited by the ACCME to provide continuing medical education for physicians.

The Institute designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by unrestricted educational grants from SUN Pharmaceutical Industries, Inc.

Mark Lebwohl, MD

Consultant: Allergan, Almirall, Arcutis, Avotres Therapeutics, BirchBioMed, Boehringer-Ingelheim, Bristol-Myers Squibb, Cora therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Foundation for Research and Education in Dermatology, Inozyme Pharma, LEO, meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/ Dr. Reddy’s abs, Theravance, Verrica

Grant/Research Support: Abbvie, Amgen, Arcutis, AstraZeneca, Boehringer Ingelheim, Celgene, Clinuvel, Eli Lilly, Incyte, Janssen Research & Development, Kadmon Corp., LEO, Medimmune, Novartis, Ortho Dermatologics, Pfizer, Sciderm UCB, ViDac

Cathy Pagano (Institute for Continuing Healthcare Education) has disclosed that she has no relevant financial relationships specific to the subject matter within the past 12 months.

[fc+222]